Management of venous thromboembolism in primary care

BMS:Pfizer

Information intended for UK healthcare professionals only.  This promotional eLearning module has been funded by Bristol Myers Squibb on behalf of the BMS/Pfizer Alliance and developed in conjunction with Guidelines.  See bottom of the page for the full disclaimer. 

View ELIQUIS (apixaban) prescribing and adverse event reporting information

 

Module objectives

  • To highlight the importance of identifying and diagnosing venous thromboembolism (VTE) in primary care
  • To review the appropriate treatment options for the short- and long-term management of VTE
  • To discuss the appropriate dosing of direct oral anticoagulants in the different phases of treatment.

The estimated time to digest this module is 1 hour.
Click here to download the certificate of completion.

Adverse events should be reported. Reporting forms and information can be found at: UK – www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store Adverse events should also be reported to Bristol-Myers Squibb via medical.information@bms.com   or 0800 731 1736 (UK)

This promotional eLearning module has been commissioned and funded by Bristol Myers Squibb on behalf of the BMS / Pfizer Alliance and developed in conjunction with GuidelinesBristol Myers Squibb  suggested the topic and presenters, and carried out full medical review and approval on all materials to ensure compliance with regulations. Bristol Myers Squibb  paid the presenters an honorarium. The views and opinions of the presenters are not necessarily those of Guidelines, its publisher, advisers, or advertisers. No part of this eLearning module may be reproduced in any form without the permission of the publisher.

432-GB-2100953
Date of preparation: February 2022